Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Guido Bocci

Showing results (21-30 of 154) with videos related to

Pageof 16
Sort By:
Frontiers in Oncology|December 5, 2019
Effects of Pazopanib Monotherapy vs. Pazopanib and Topotecan Combination on Anaplastic Thyroid Cancer CellsTeresa Di Desidero, Paola Orlandi, Daniela Gentile, et al.
Pharmacogenomics|December 26, 2006
Vascular endothelial growth factor pharmacogenetics: a new perspective for anti-angiogenic therapyGiuseppe Pasqualetti, Romano Danesi, Mario Del Tacca, et al.
Pharmacological Research|June 7, 2020
Opioid receptors beyond pain control: The role in cancer pathology and the debated importance of their pharmacological modulationMarco Carli, Sandra Donnini, Carolina Pellegrini, et al.
Biochimica Et Biophysica Acta. Reviews on Cancer|August 10, 2025
GABAergic signaling in colorectal cancer: Mechanistic insights, tumor microenvironment crosstalk, and therapeutic opportunitiesDonghao Tang, Paola Orlandi, Qijie Li, et al.
European Journal of Pharmacology|September 27, 2003
Selective anti-endothelial effects of protracted low-dose BAL-9504, a novel geranylgeranyl-transferase inhibitorGuido Bocci, Romano Danesi, Mario Del Tacca, et al.
Current Clinical Pharmacology|August 1, 2008
Clinical pharmacokinetics of irinotecan-based chemotherapy in colorectal cancer patientsAntonello Di Paolo, Guido Bocci, Romano Danesi, et al.
Pharmacological Research|April 12, 2020
Epileptogenesis and oncogenesis: An antineoplastic role for antiepileptic drugs in brain tumours?Federico Cucchiara, Francesco Pasqualetti, Filippo Sean Giorgi, et al.
Proceedings of the National Academy of Sciences of the United States of America|October 17, 2003
Thrombospondin 1, a mediator of the antiangiogenic effects of low-dose metronomic chemotherapyGuido Bocci, Giulio Francia, Shan Man, et al.
Toxicology and Applied Pharmacology|February 16, 2005
5-Fluorouracil catabolism to 5-fluoro-5,6-dihydrouracil is reduced by acute liver impairment in miceFederico Innocenti, Romano Danesi, Guido Bocci, et al.
Current Oncology Reports|March 6, 2024
Metronomic Chemotherapy in Elderly PatientsArianna Bandini, Pasquale Fabio Calabrò, Marta Banchi, et al.
Pageof 16

Showing results (21-30 of 154) with videos related to

Sort By:
Pageof 16
Frontiers in Oncology|December 5, 2019
Effects of Pazopanib Monotherapy vs. Pazopanib and Topotecan Combination on Anaplastic Thyroid Cancer CellsTeresa Di Desidero, Paola Orlandi, Daniela Gentile, et al.
Pharmacogenomics|December 26, 2006
Vascular endothelial growth factor pharmacogenetics: a new perspective for anti-angiogenic therapyGiuseppe Pasqualetti, Romano Danesi, Mario Del Tacca, et al.
Pharmacological Research|June 7, 2020
Opioid receptors beyond pain control: The role in cancer pathology and the debated importance of their pharmacological modulationMarco Carli, Sandra Donnini, Carolina Pellegrini, et al.
Biochimica Et Biophysica Acta. Reviews on Cancer|August 10, 2025
GABAergic signaling in colorectal cancer: Mechanistic insights, tumor microenvironment crosstalk, and therapeutic opportunitiesDonghao Tang, Paola Orlandi, Qijie Li, et al.
European Journal of Pharmacology|September 27, 2003
Selective anti-endothelial effects of protracted low-dose BAL-9504, a novel geranylgeranyl-transferase inhibitorGuido Bocci, Romano Danesi, Mario Del Tacca, et al.
Current Clinical Pharmacology|August 1, 2008
Clinical pharmacokinetics of irinotecan-based chemotherapy in colorectal cancer patientsAntonello Di Paolo, Guido Bocci, Romano Danesi, et al.
Pharmacological Research|April 12, 2020
Epileptogenesis and oncogenesis: An antineoplastic role for antiepileptic drugs in brain tumours?Federico Cucchiara, Francesco Pasqualetti, Filippo Sean Giorgi, et al.
Proceedings of the National Academy of Sciences of the United States of America|October 17, 2003
Thrombospondin 1, a mediator of the antiangiogenic effects of low-dose metronomic chemotherapyGuido Bocci, Giulio Francia, Shan Man, et al.
Toxicology and Applied Pharmacology|February 16, 2005
5-Fluorouracil catabolism to 5-fluoro-5,6-dihydrouracil is reduced by acute liver impairment in miceFederico Innocenti, Romano Danesi, Guido Bocci, et al.
Current Oncology Reports|March 6, 2024
Metronomic Chemotherapy in Elderly PatientsArianna Bandini, Pasquale Fabio Calabrò, Marta Banchi, et al.
Pageof 16